1. Summarize the clinical benefit and risks of anti-body drug conjugates as new treatments for metastatic breast cancer
  2. Apply the results from new clinical studies with CDK4/6 inhibitors in Hormone receptor positive, Her2 metastatic breast cancer
  3. Identify practice-changing insights for treating metastatic melanoma patients
  4. Outline a roadmap for continued progress in the melanoma clinic
  5. Summarize the potential benefit of neoadjuvant systemic treatment for stage III melanoma
  6. Explain the benefit of nivolumab/relatlimab in treatment of advanced stage melanoma


Zoom info: https://uwmadison.zoom.us/s/92969244579?pwd=NzBCQXNDYU5oYlliajdZZ3A1M2Qzdz09

Session date: 
10/05/2022 - 8:00am to 9:00am CDT
In-person and Virtually
750 Highland Avenue (HSLC)
HSLC 1306
Madison, WI 53705
United States
  • 1.00 AAPA Category 1 CME
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 ACPE Contact Hours - Pharmacist Technician
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™

Please login or register to take this course.
Discloser List CME Internal Report
Dr. Vince Ma
Dr. Mark Albertini
Dr. Kari Braun Wisinski